Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2022

Celebrating 25 years
of Continuous Growth
and Improvement in
Animal Health and Welfare

Download a PDF of the 2022 Annual Report

Dechra marks its 25th year anniversary since its inception in 1997.

The last 25 years were marked by many milestones, the completion of a number of acquisitions and growth of its footprint across the Globe.

Key Highlights

* For the year ended 30 June 1998.
† Monthly average.

Top Ten

Key Strategic Developments Over 25 Years



Financial Performance

  • Revenue growth of 13.8% to £681.8 million
  • Underlying operating profit increased by 9.4% to £174.3 million
  • Reported operating profit increased by 16.2% to £95.5 million
  • Strong cash generation of £163.3 million representing cash conversion of 93.7%
  • Underlying diluted EPS increase of 14.0% to 120.84 pence
  • Full year dividend increased by 10.8% to 44.8 pence
  • Strong organic growth in all key markets and across all therapeutic segments
  • Pipeline strengthened through own innovation and acquisition
  • International portfolio strengthened through numerous product approvals
  • Successfully completed two material company acquisitions post year-end: Piedmont and Med-Pharmex
  • Executed numerous bolt-on product acquisitions to complement existing equine and CAP portfolios

Download a PDF of The Highlights

Our Product Pipeline

A key strategic priority for the Group is the delivery and strength of the pipeline. We currently have 41 projects in the product development process:

Download a PDF of our Product Development



We have delivered another strong set of financial results and we continue to execute our strategy successfully."

Alison Platt

Chief Executive
Officer’s Statement

We have continued to progress on all aspects of our strategy; the product development pipeline was strengthened, material acquisitions were completed post year-end and a new subsidiary was established in South Korea as we continue our geographical expansion."

Ian Page

Download a PDF of the
Chief Executive Officer's Statement


Our excellent trading performance has been facilitated by a robust global supply chain, supplemented by healthy contributions from our product acquisitions in the year."

Paul Sandland

Download a PDF of the
Financial Review

Our Key Strengths

As well as our ability to impact the Animal, Health and Welfare industry globally with our breadth of products and strong and innovative product pipeline, we have a key set of strengths, summarised below:

Download a PDF of our Key Strengths

Our Values and Culture

Our Values, entrepreneurial attitude and agile approach to the way we do things are the backbone of our Culture.

Everything we do is underpinned by our Culture and Values. They are important to us and have helped drive the Group’s success. We believe that our Values encapsulate our business ethics and set out the standards that we wish to achieve and ultimately exceed. They outline the type of people we are, the services we provide and the way we aim to do business. We deliver high quality products and services to veterinarians worldwide through our employees and a network of third parties with the aim of sustainably improving global animal health and welfare.







Visit our dedicated online
Sustainability Report

We are making a difference through the sustainable
improvement in global animal health and welfare.

Our Sustainability Report

View our online Sustainability Report